Janux Therapeutics (NASDAQ:JANX) Price Target Lowered to $41.00 at Scotiabank

Janux Therapeutics (NASDAQ:JANX) had its price objective lowered by research analysts at Scotiabank from $62.00 to $41.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “sector perform” rating on the stock. Scotiabank’s price target indicates a potential upside of 24.66% from the stock’s current price.

JANX has been the topic of a number of other reports. Stifel Nicolaus boosted their target price on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Leerink Partners boosted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Finally, HC Wainwright boosted their target price on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $88.00.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock traded up $0.88 during trading on Friday, hitting $32.89. The stock had a trading volume of 979,853 shares, compared to its average volume of 1,025,086. The firm has a market cap of $1.73 billion, a P/E ratio of -28.11 and a beta of 3.16. The business has a fifty day moving average of $44.22 and a two-hundred day moving average of $47.83. Janux Therapeutics has a fifty-two week low of $31.69 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, research analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. This represents a 3.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the transaction, the chief executive officer now directly owns 217,054 shares in the company, valued at approximately $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 61,668 shares of company stock valued at $3,582,515 in the last three months. Insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of JANX. Russell Investments Group Ltd. boosted its stake in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after acquiring an additional 442 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Janux Therapeutics during the 4th quarter worth about $59,000. Plato Investment Management Ltd boosted its stake in shares of Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares in the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Janux Therapeutics during the 4th quarter worth about $139,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.